IPCA Labs share price has plunged 3% and is presently trading at Rs 1,561.1.
Meanwhile, the BSE HEALTHCARE index is at 43,168.5 (down 0.5%).
Among the top losers in the BSE HEALTHCARE index today are POLY MEDICURE (down 7.2%) and FORTIS HEALTHCARE (down 3.6%).
CAPLIN POINT (up 5.5%) and MAX HEALTHCARE INSTITUTE (up 3.8%) are among the top gainers today.
Over the last one year, IPCA Labs has moved up from Rs 1,089.1 to Rs 1,561.1, registering a gain of Rs 472.0 (up 43.3%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,918.9 to 43,168.5, registering a gain of 44.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 168.2%), SUVEN PHARMACEUTICALS (up 110.7%) and Glenmark Pharma (up 95.6%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 79,861.8 (down 0.3%).
The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 3.3%) and Ultratech Cement (down 2.6%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,148.1 (down 0.3%). Adani Enterprises and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.2 to 79,861.8, registering a gain of 13,838.5 points (up 21.0%).
IPCA Labs net profit grew 78.6% YoY to Rs 2,454 million for the quarter ended September 2024, compared to a profit of Rs 1,374 million a year ago. Net sales rose 15.8% to Rs 23,549 million during the period as against Rs 20,340 million in July-September 2023.
For the year ended March 2024, IPCA Labs reported 7.6% increase in net profit to Rs 5,292 million compared to net profit of Rs 4,919 million during FY23. Revenue of the company grew 23.6% to Rs 76,198 million during FY24.
The current Price to earnings ratio of IPCA Labs, based on rolling 12 month earnings, stands at 59.1.
Equitymaster requests your view! Post a comment on "IPCA Labs Plunges 3%; BSE HEALTHCARE Index Down 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!